title: Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy.
abstract: Eribulin mesylate (E7389, INN:eribulin mesilate Halaven(®)) is a non-taxane microtubule dynamics inhibitor currently in clinical use for advanced breast cancer. Other microtubule-targeting agents for breast cancer, including paclitaxel and ixabepilone, display a common treatment dose-limiting toxicity of peripheral neuropathy (PN). In an earlier study, we found eribulin mesylate had a lower propensity to induce PN in mice than either paclitaxel or ixabepilone. In the current study, we compared additional PN induced by paclitaxel versus eribulin mesylate when administered to mice with preexisting paclitaxel-induced PN. Initially, paclitaxel at 0.75 × its maximum tolerated dose (MTD; 22.5 mg/kg) was given on a Q2Dx3 regimen for 2 weeks. The second chemotherapy was 0.5 MTD eribulin mesylate (0.875 mg/kg) or paclitaxel (15 mg/kg) on a similar regimen, starting 2 weeks after the first. Initial paclitaxel treatment produced significant decreases in caudal nerve conduction velocity (NCV; averaging 19.5 ± 1 and 22.2 ± 1.3 %, p < 0.001) and amplitude (averaging 53.2 ± 2.6 and 72.4 ± 2.1 %, p < 0.001) versus vehicle when measured 24 h or 2 weeks after dosing cessation, respectively. Additional 0.5 MTD paclitaxel further reduced caudal NCV and amplitude relative to immediately before initiation of the second regimen (by 11 ± 2.1 and 59.2 ± 5 %, p < 0.01, respectively). In contrast, 0.5 MTD eribulin mesylate caused no further decrease in caudal NCV. In conclusion, unlike additional paclitaxel treatment, eribulin mesylate administered to mice with preexisting paclitaxel-induced PN had limited additional deleterious effects at 6 weeks. These preclinical data suggest that eribulin mesylate may have reduced tendency to exacerbate preexisting paclitaxel-induced PN in clinical settings.
authors: NeuroTranslational Drug Discovery Program, Brain Science Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.
authors: Krystyna M
authors: KM
authors: Wozniak
authors: Ying
authors: Y
authors: Wu
authors: Mohamed H
authors: MH
authors: Farah
authors: Bruce A
authors: BA
authors: Littlefield
authors: Kenichi
authors: K
authors: Nomoto
authors: Barbara S
authors: BS
authors: Slusher
mesh_terms: D000818:Animals; D005260:Female; D005663:Furans / Q000633:toxicity*; D007659:Ketones / Q000633:toxicity*; D051379:Mice; D008807:Mice, Inbred BALB C; D009431:Neural Conduction / Q000187:drug effects / Q000502:physiology; D017239:Paclitaxel / Q000633:toxicity*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000473:pathology* / Q000503:physiopathology; D011897:Random Allocation; D050257:Tubulin Modulators / Q000633:toxicity*; D000095662:Polyether Polyketides
chemical_list: D005663:Furans; D007659:Ketones; D017239:Paclitaxel; D050257:Tubulin Modulators; C490954:eribulin; D000095662:Polyether Polyketides
references: Neurotoxicology. 1997;18(1):137-45
references: 9215996
references: Cancer Res. 2011 Jun 1;71(11):3952-62
references: 21498637
references: Neurology. 1989 Mar;39(3):368-73
references: 2564647
references: Brain. 2004 Mar;127(Pt 3):671-9
references: 14761904
references: Neurotherapeutics. 2009 Oct;6(4):620-9
references: 19789067
references: Semin Oncol. 1993 Aug;20(4 Suppl 3):1-15
references: 8102012
references: J Clin Oncol. 1997 May;15(5):1965-73
references: 9164208
references: Exp Neurol. 1995 Mar;132(1):16-23
references: 7536686
references: Brain Res. 2000 Dec 29;887(2):239-49
references: 11134612
references: Breast Cancer. 2004;11(1):82-5
references: 14718798
references: Exp Neurol. 1995 May;133(1):64-72
references: 7601264
references: Pain. 2001 Dec;94(3):293-304
references: 11731066
references: J Clin Oncol. 1996 Jul;14(7):1993-9
references: 8683229
references: Clin Cancer Res. 2011 Nov 1;17(21):6615-22
references: 21859830
references: J Chemother. 2004 Nov;16 Suppl 4:83-5
references: 15688618
references: J Neuropathol Exp Neurol. 1993 Nov;52(6):553-60
references: 7693878
references: Mol Cancer Ther. 2005 Jul;4(7):1086-95
references: 16020666
references: Mol Cancer Ther. 2009 Aug;8(8):2086-95
references: 19671735
references: Breast Cancer. 2004;11(1):92-9
references: 14718800
references: Ann Neurol. 1998 Jan;43(1):46-55
references: 9450768
references: Neurotoxicology. 2000 Aug;21(4):513-20
references: 11022860
references: Mol Cancer Ther. 2008 Jul;7(7):2003-11
references: 18645010
references: Neuroscience. 2001;108(3):507-15
references: 11738263
references: Crit Rev Oncol Hematol. 2012 Feb;81(2):163-84
references: 21493087
references: Drugs Today (Barc). 2010 Sep;46(9):641-53
references: 20967296
references: J Natl Cancer Inst Monogr. 1993;(15):25-37
references: 7912527
references: Clin Cancer Res. 2003 Nov 15;9(15):5756-67
references: 14654561
references: Ann Neurol. 1991 Jan;29(1):87-90
references: 1705109
references: J Clin Oncol. 1987 Aug;5(8):1232-9
references: 2887641
references: J Neurooncol. 1999 Jan;41(2):107-16
references: 10222430
references: Mol Pharmacol. 2006 Dec;70(6):1866-75
references: 16940412
references: J Natl Cancer Inst Monogr. 1993;(15):107-15
references: 7912516
references: Cancer. 1995 Mar 1;75(5):1141-50
references: 7850713
references: J Clin Oncol. 2009 Jun 20;27(18):2954-61
references: 19349550
references: Br J Cancer. 2003 Dec;89 Suppl 3:S16-22
references: 14661042